ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
Abbott beats quarterly profit estimates on strong medical device sales
April 2 (Reuters) - A federal appeals court on Tuesday upheld the dismissal of a proposed class action by parents who say they overpaid for Abbott Laboratories' (ABT.N), opens new tab baby formula before one of its plants was shuttered for unsanitary conditions.The parents had urged the Chicago-based 7th U.S. Circuit Court of Appeals to conclude they had legal standing to sue Abbott, arguing that they would not have paid the purchase
April 2 (Reuters) - Abbott Laboratories (ABT.N), opens new tab said on Tuesday the U.S. FDA has approved its heart valve repair device for patients with a potentially fatal heart disease, just months after rival Edwards
ABBOTT PARK, Ill., April 1, 2024 /PRNewswire/ -- Abbott's i-STAT TBI cartridge has received clearance from the U.S. Food and Drug Administration (FDA) to be used with whole blood, allowing doctors to help assess patients with suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests to help with the assessment of TBI were only cleared for use with plasma or serum, requiring samples to be sent to a lab for processing and testing.
ABBOTT PARK, Ill., March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.
Abbott has secured a CE mark approval in Europe for its long-term insertable cardiac monitor, designed to help monitor a patient’s heart rhythms remotely for up to six years.
Real-World Data Show Abbott's FreeStyle Libre® Systems
Abbott Declares 401st Consecutive Quarterly Dividend
Abbott's heart valve repair device gets FDA advisers' backing